[
  {
    "ts": null,
    "headline": "Kenvue Inc. (KVUE): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Kenvue Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on KVUE. Kenvue Inc.’s share was trading at $18.66 as of February 19th. KVUE’s trailing and forward P/E were 24.93 and 17.01, respectively according to Yahoo Finance. Kenvue, the newly independent consumer health company spun […]",
    "url": "https://finnhub.io/api/news?id=12502be7c9c5391c7be5e1717f7d25972239c38914c549f1fe754cc1d6451271",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772294102,
      "headline": "Kenvue Inc. (KVUE): A Bull Case Theory",
      "id": 139265371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Kenvue Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on KVUE. Kenvue Inc.’s share was trading at $18.66 as of February 19th. KVUE’s trailing and forward P/E were 24.93 and 17.01, respectively according to Yahoo Finance. Kenvue, the newly independent consumer health company spun […]",
      "url": "https://finnhub.io/api/news?id=12502be7c9c5391c7be5e1717f7d25972239c38914c549f1fe754cc1d6451271"
    }
  },
  {
    "ts": null,
    "headline": "Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap?",
    "summary": "Middleby is splitting up, and the sum-of-the-parts math looks promising if margins cooperate.",
    "url": "https://finnhub.io/api/news?id=66ed5939b946de38ed6ec7876c432c60831774c9900a765e337243553c1266a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772292300,
      "headline": "Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap?",
      "id": 139264431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Middleby is splitting up, and the sum-of-the-parts math looks promising if margins cooperate.",
      "url": "https://finnhub.io/api/news?id=66ed5939b946de38ed6ec7876c432c60831774c9900a765e337243553c1266a5"
    }
  },
  {
    "ts": null,
    "headline": "Why Your Retirement Portfolio Takes Years To Get Right",
    "summary": "Why Your Retirement Portfolio Takes Years To Get Right",
    "url": "https://finnhub.io/api/news?id=352b2ba83e1133ff3de5095a149f27e49fec2911dc32f8ea06b7377ae8d3d700",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772269200,
      "headline": "Why Your Retirement Portfolio Takes Years To Get Right",
      "id": 139263227,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=352b2ba83e1133ff3de5095a149f27e49fec2911dc32f8ea06b7377ae8d3d700"
    }
  },
  {
    "ts": null,
    "headline": "Is Blackstone Inc. (BX) One of the Best Cheap Blue Chip Stocks to Buy According to Analysts?",
    "summary": "Blackstone Inc. (NYSE:BX) is one of the best cheap blue chip stocks to buy according to analysts. Blackstone Inc. (NYSE:BX) reported on February 23 that Blackstone Life Sciences (BXLS) announced a research and development funding agreement to advance the clinical development of bleximenib, which is an investigational oral menin inhibitor, for acute myeloid leukemia (AML). […]",
    "url": "https://finnhub.io/api/news?id=c28db10598e67c9f3f54d6d8fa9cc8202b9176f1f266b090a506f7511a2a51d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772263099,
      "headline": "Is Blackstone Inc. (BX) One of the Best Cheap Blue Chip Stocks to Buy According to Analysts?",
      "id": 139260959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Blackstone Inc. (NYSE:BX) is one of the best cheap blue chip stocks to buy according to analysts. Blackstone Inc. (NYSE:BX) reported on February 23 that Blackstone Life Sciences (BXLS) announced a research and development funding agreement to advance the clinical development of bleximenib, which is an investigational oral menin inhibitor, for acute myeloid leukemia (AML). […]",
      "url": "https://finnhub.io/api/news?id=c28db10598e67c9f3f54d6d8fa9cc8202b9176f1f266b090a506f7511a2a51d8"
    }
  },
  {
    "ts": null,
    "headline": "Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?",
    "summary": "If you are wondering whether Johnson & Johnson is still fairly priced after its recent run, this article will help you weigh what you are paying against what you are getting. The stock last closed at US$248.43, with reported returns of 2.4% over 7 days, 9.1% over 30 days, 19.8% year to date, 54.7% over 1 year and 83.3% over 5 years. These figures may have some investors reassessing both upside potential and risk. Recent headlines around Johnson & Johnson have continued to focus on its...",
    "url": "https://finnhub.io/api/news?id=52a9ec290e473bfd879fcd56ab11cc967bcb035b3b5291267197cc40cdb2ba8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772241299,
      "headline": "Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?",
      "id": 139258810,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you are wondering whether Johnson & Johnson is still fairly priced after its recent run, this article will help you weigh what you are paying against what you are getting. The stock last closed at US$248.43, with reported returns of 2.4% over 7 days, 9.1% over 30 days, 19.8% year to date, 54.7% over 1 year and 83.3% over 5 years. These figures may have some investors reassessing both upside potential and risk. Recent headlines around Johnson & Johnson have continued to focus on its...",
      "url": "https://finnhub.io/api/news?id=52a9ec290e473bfd879fcd56ab11cc967bcb035b3b5291267197cc40cdb2ba8e"
    }
  }
]